Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib + Sacituzumab Govitecan in TNBC
NCT05113966Phase 2Terminated
- Sponsor
- G1 Therapeutics, Inc.
- Start
- Dec 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trilaciclib in triple negative breast cancer (TNBC), sponsored by G1 Therapeutics, Inc. Primary endpoint: Progression Free Survival up to 23 months. Started Dec 2021; status: terminated.
02
Drugs
trilaciclib
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05113966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113966.